A tale of two factors: What determines the rate of progression in Huntington's disease? A longitudinal MRI study

Movement Disorders

Volumn 26, Issue 9, 2011, Pages 1691-1697

  Rosas, H Diana ^a   Reuter, Martin ^a,b,d   Doros, Gheorghe ^c   Lee, Stephanie Y ^a   Triggs, Tyler ^a   Malarick, Keith ^a   Fischl, Bruce ^a,b,d   Salat, David H ^a,d   Hersch, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BOSTON UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Huntington's disease; Magnetic resonance imaging longitudinal atrophy; Neurodegeneration; Phenotypic variability

Indexed keywords

ADULT; ARTICLE; BASAL GANGLION; BRAIN ATROPHY; BRAIN CORTEX; BRAIN REGION; CAG REPEAT; CLINICAL ARTICLE; DISEASE COURSE; ENVIRONMENTAL FACTOR; EPIGENETICS; FEMALE; FRONTAL CORTEX; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MALE; NERVE DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARIETAL CORTEX; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SENSORIMOTOR CORTEX; SYMPTOM; WHITE MATTER;

AGE OF ONSET; ATROPHY; CEREBRAL CORTEX; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; TRINUCLEOTIDE REPEATS;

EID: 79961208186     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23762     Document Type: Article

References (26)

1. Kieburtz K, MacDonald M, Shih C, et al. Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet. 1994; 31: 872-874.
2. Ravina B, Romer M, Constantinescu R, et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord. 2008; 23: 1223-1227.
3. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology. 2006; 66: 1016-1020.
4. Group HS. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996; 11: 136-142.
5. Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008; 131: 1057-1068.
6. Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001; 20: 70-80.
7. Han X, Jovicich J, Salat D, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage. 2006; 32: 180-194.
8. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. Cereb Cortex. 2004; 14: 721-730.
9. Reuter M, Rosas HD, Fischl B. Highly accurate inverse consistent registration: a robust approach. Neuroimage. 2010; 53: 1181-1196.
10. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002; 33: 341-355.
11. Rosas HD, Lee SY, Bender AC, et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection." Neuroimage. 2010; 49: 2995-3004.
12. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006; 31: 961-980.
13. Berry DA, Ayers GD. Symmetrized percent change for treatment comparisons. Am Statistician. 2006; 60: 27-31.
14. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
15. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. One-year brain atrophy evident in healthy aging. J Neurosci. 2009; 29: 15223-15231.
16. Thu DC, Oorschot DE, Tippett LJ, et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010; 133: 1094-1110.
17. Aylward EH, Li Q, Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology. 1997; 48: 394-399.
18. Henley SM, Wild EJ, Hobbs NZ, et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol. 2009; 256: 203-212.
19. Jenkins BG, Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology. 1998; 50: 1357-1365.
20. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000; 54: 452-458.
21. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol. 2007; 83: 228-248.
22. Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett. 1999; 272: 53-56.
23. Kovtun IV, Liu Y, Bjoras M, Klungland A, Wilson SH, McMurray CT. OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature. 2007; 447: 447-452.
24. Horton TM, Graham BH, Corral-Debrinski M, et al. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 1995; 45: 1879-1883.
25. Feigin A, Leenders KL, Moeller JR, et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med. 2001; 42: 1591-1595.
26. van Dellen A, Hannan AJ. Genetic and environmental factors in the pathogenesis of Huntington's disease. Neurogenetics. 2004; 5: 9-17.